Lenvatinib with pembrolizumab and transarterial chemoembolization for untreated localised hepatocellular carcinoma [ID5117]
In development
Reference number: GID-TA11008
Expected publication date: TBC
Please note that following on from advice received from the company this appraisal has been scheduled back into the work programme to align with latest regulatory expectations.
Therefore, we now anticipate that the appraisal will begin during late November 2025 when we will write to stakeholders about how they can get involved.